A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. (2022)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00277-022-04853-4

PubMed Identifier: 35488900

Publication URI: http://europepmc.org/abstract/MED/35488900

Type: Journal Article/Review

Volume: 101

Parent Publication: Annals of hematology

Issue: 8

ISSN: 0939-5555